AlphaMa
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
AI-driven biotech using integrated DEL-AI platform to accelerate discovery of small molecule drugs in oncology and metabolic diseases.
OncologyMetabolic
Technology Platform
Integrated DEL-AI (DELAI) platform combining DNA-encoded library screening with artificial intelligence algorithms for target validation and hit-to-lead optimization.
Opportunities
Growing demand for AI-driven drug discovery solutions, expansion into additional therapeutic areas beyond oncology and metabolic diseases, and potential to license platform technology to multiple pharmaceutical partners.
Risk Factors
Heavy competition in AI drug discovery space, unproven track record of advancing candidates to clinical stages, and dependency on partnership revenue rather than proprietary pipeline.
Competitive Landscape
Competes with other AI-driven drug discovery companies like Insilico Medicine, Exscientia, and Schrödinger, but differentiates through integrated DEL-AI platform combining experimental data generation with computational prediction.